TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global and United States Monoclonal antibodies (mAbs) Biosimilars Market Report & Forecast 2022-2028

Global and United States Monoclonal antibodies (mAbs) Biosimilars Market Report & Forecast 2022-2028

  • Category:Life Sciences
  • Published on : 28 September 2022
  • Pages :90
  • Formats:
  • Report Code:SMR-7395259
OfferClick for best price

Best Price: $3480

Monoclonal antibodies mAbs Biosimilars Market Size, Share 2022


Market Analysis and Insights: Global Monoclonal antibodies mAbs Biosimilars Market

The global Monoclonal antibodies mAbs Biosimilars market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Monoclonal antibodies mAbs Biosimilars market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Monoclonal antibodies mAbs Biosimilars market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Monoclonal antibodies mAbs Biosimilars market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Monoclonal antibodies mAbs Biosimilars market.

Global Monoclonal antibodies mAbs Biosimilars Scope and Market Size

Monoclonal antibodies (mAbs) Biosimilars market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Monoclonal antibodies (mAbs) Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Monoclonal antibodies (mAbs) Biosimilars market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type

  • Erythropoietin (EPO)
  • Human Growth Hormone (HGH)
  • Granulocyte- Colony Stimulating Factor (G-CSF)
  • Monoclonal Antibody (mAb)
  • Insulin
  • Interferon (IFN)
  • Others

Segment by Application

  • Anti-Cancer
  • Anti-Inflammatory/Autoimmune

By Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Taiwan
  • Indonesia
  • Thailand
  • Malaysia
  • Philippines
  • Vietnam
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • U.A.E

By Company

  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • Hospira
  • 3SBio
  • Accord Healthcare
  • AET Biotech
  • Allergan
  • Amega Biotech

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Monoclonal antibodies mAbs Biosimilars product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Monoclonal antibodies mAbs Biosimilars, with price, sales, revenue, and global market share of Monoclonal antibodies mAbs Biosimilars from 2019 to 2022.

Chapter 3, the Monoclonal antibodies mAbs Biosimilars competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Monoclonal antibodies mAbs Biosimilars breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Monoclonal antibodies mAbs Biosimilars market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Monoclonal antibodies mAbs Biosimilars.

Chapter 13, 14, and 15, to describe Monoclonal antibodies mAbs Biosimilars sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Monoclonal antibodies mAbs Biosimilars Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global and United States Monoclonal antibodies (mAbs) Biosimilars Market Report & Forecast 2022-2028
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 90 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Study Coverage
1.1 Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million) Introduction
1.2 Global Monoclonal antibodies (mAbs) Biosimilars Outlook 2017 VS 2022 VS 2028
1.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size for the Year 2017-2028
1.2.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Size for the Year 2017-2028
1.3 Monoclonal antibodies (mAbs) Biosimilars Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Monoclonal antibodies (mAbs) Biosimilars in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Monoclonal antibodies (mAbs) Biosimilars Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Monoclonal antibodies (mAbs) Biosimilars Market Dynamics
1.4.1 Monoclonal antibodies (mAbs) Biosimilars Industry Trends
1.4.2 Monoclonal antibodies (mAbs) Biosimilars Market Drivers
1.4.3 Monoclonal antibodies (mAbs) Biosimilars Market Challenges
1.4.4 Monoclonal antibodies (mAbs) Biosimilars Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Monoclonal antibodies (mAbs) Biosimilars by Type
2.1 Monoclonal antibodies (mAbs) Biosimilars Market Segment by Type
2.1.1 Erythropoietin (EPO)
2.1.2 Human Growth Hormone (HGH)
2.1.3 Granulocyte- Colony Stimulating Factor (G-CSF)
2.1.4 Monoclonal Antibody (mAb)
2.1.5 Insulin
2.1.6 Interferon (IFN)
2.1.7 Others
2.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2017, 2022 & 2028)
2.3 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2017-2028)
2.4 United States Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2017, 2022 & 2028)
2.5 United States Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2017-2028)
3 Monoclonal antibodies (mAbs) Biosimilars by Application
3.1 Monoclonal antibodies (mAbs) Biosimilars Market Segment by Application
3.1.1 Anti-Cancer
3.1.2 Anti-Inflammatory/Autoimmune
3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2017, 2022 & 2028)
3.3 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2017-2028)
3.4 United States Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2017, 2022 & 2028)
3.5 United States Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2017-2028)
4 Global Monoclonal antibodies (mAbs) Biosimilars Competitor Landscape by Company
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Company
4.1.1 Top Global Monoclonal antibodies (mAbs) Biosimilars Companies Ranked by Revenue (2021)
4.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Player (2017-2022)
4.2 Global Monoclonal antibodies (mAbs) Biosimilars Concentration Ratio (CR)
4.2.1 Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Monoclonal antibodies (mAbs) Biosimilars in 2021
4.2.3 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Monoclonal antibodies (mAbs) Biosimilars Headquarters, Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million) Type
4.3.1 Global Monoclonal antibodies (mAbs) Biosimilars Headquarters and Area Served
4.3.2 Global Monoclonal antibodies (mAbs) Biosimilars Companies Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Monoclonal antibodies (mAbs) Biosimilars Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Monoclonal antibodies (mAbs) Biosimilars Market Size by Company
4.5.1 Top Monoclonal antibodies (mAbs) Biosimilars Players in United States, Ranked by Revenue (2021)
4.5.2 United States Monoclonal antibodies (mAbs) Biosimilars Revenue by Players (2020, 2021 & 2022)
5 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region
5.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2017-2028)
5.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region: 2017-2022
5.2.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth 2017-2028
6.1.2 North America Monoclonal antibodies (mAbs) Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth 2017-2028
6.3.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth 2017-2028
6.4.2 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Biocon
7.1.1 Biocon Company Details
7.1.2 Biocon Business Overview
7.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Introduction
7.1.4 Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
7.1.5 Biocon Recent Development
7.2 Celltrion
7.2.1 Celltrion Company Details
7.2.2 Celltrion Business Overview
7.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Introduction
7.2.4 Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
7.2.5 Celltrion Recent Development
7.3 Dr. Reddy's Laboratories
7.3.1 Dr. Reddy's Laboratories Company Details
7.3.2 Dr. Reddy's Laboratories Business Overview
7.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Introduction
7.3.4 Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
7.3.5 Dr. Reddy's Laboratories Recent Development
7.4 Hospira
7.4.1 Hospira Company Details
7.4.2 Hospira Business Overview
7.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Introduction
7.4.4 Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
7.4.5 Hospira Recent Development
7.5 3SBio
7.5.1 3SBio Company Details
7.5.2 3SBio Business Overview
7.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Introduction
7.5.4 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
7.5.5 3SBio Recent Development
7.6 Accord Healthcare
7.6.1 Accord Healthcare Company Details
7.6.2 Accord Healthcare Business Overview
7.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Introduction
7.6.4 Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
7.6.5 Accord Healthcare Recent Development
7.7 AET Biotech
7.7.1 AET Biotech Company Details
7.7.2 AET Biotech Business Overview
7.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
7.7.4 AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
7.7.5 AET Biotech Recent Development
7.8 Allergan
7.8.1 Allergan Company Details
7.8.2 Allergan Business Overview
7.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Introduction
7.8.4 Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
7.8.5 Allergan Recent Development
7.9 Amega Biotech
7.9.1 Amega Biotech Company Details
7.9.2 Amega Biotech Business Overview
7.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
7.9.4 Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
7.9.5 Amega Biotech Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Monoclonal antibodies (mAbs) Biosimilars Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
Table 2. Monoclonal antibodies (mAbs) Biosimilars Market Trends
Table 3. Monoclonal antibodies (mAbs) Biosimilars Market Drivers
Table 4. Monoclonal antibodies (mAbs) Biosimilars Market Challenges
Table 5. Monoclonal antibodies (mAbs) Biosimilars Market Restraints
Table 6. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Monoclonal antibodies (mAbs) Biosimilars Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Monoclonal antibodies (mAbs) Biosimilars Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Monoclonal antibodies (mAbs) Biosimilars Companies in Global Market, Ranking by Revenue (2021)
Table 11. Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Player, (US$ Million), 2017-2022
Table 12. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Player, 2017-2022
Table 13. Global Monoclonal antibodies (mAbs) Biosimilars Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Monoclonal antibodies (mAbs) Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2021)
Table 15. Top Players of Monoclonal antibodies (mAbs) Biosimilars in Global Market, Headquarters and Area Served
Table 16. Companies Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million) Type
Table 17. Date of International Companies Enter into Monoclonal antibodies (mAbs) Biosimilars Market
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Top Monoclonal antibodies (mAbs) Biosimilars Players in United States Market, Ranking by Revenue (2021)
Table 20. United States Monoclonal antibodies (mAbs) Biosimilars Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 21. United States Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Players, 2020, 2021 & 2022
Table 22. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 23. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2017-2022) & (US$ Million)
Table 24. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Forecast by Region (2023-2028) & (US$ Million)
Table 25. North America Monoclonal antibodies (mAbs) Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
Table 26. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Sales in Value by Region (2017-2028) & (US$ Million)
Table 27. Europe Monoclonal antibodies (mAbs) Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
Table 28. Latin Americaa Monoclonal antibodies (mAbs) Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
Table 29. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
Table 30. Biocon Company Details
Table 31. Biocon Business Overview
Table 32. Biocon Monoclonal antibodies (mAbs) Biosimilars Product
Table 33. Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 34. Biocon Recent Development
Table 35. Celltrion Company Details
Table 36. Celltrion Business Overview
Table 37. Celltrion Monoclonal antibodies (mAbs) Biosimilars Product
Table 38. Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 39. Celltrion Recent Development
Table 40. Dr. Reddy's Laboratories Company Details
Table 41. Dr. Reddy's Laboratories Business Overview
Table 42. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product
Table 43. Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 44. Dr. Reddy's Laboratories Recent Development
Table 45. Hospira Company Details
Table 46. Hospira Business Overview
Table 47. Hospira Monoclonal antibodies (mAbs) Biosimilars Product
Table 48. Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 49. Hospira Recent Development
Table 50. 3SBio Company Details
Table 51. 3SBio Business Overview
Table 52. 3SBio Monoclonal antibodies (mAbs) Biosimilars Product
Table 53. 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 54. 3SBio Recent Development
Table 55. Accord Healthcare Company Details
Table 56. Accord Healthcare Business Overview
Table 57. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product
Table 58. Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 59. Accord Healthcare Recent Development
Table 60. AET Biotech Company Details
Table 61. AET Biotech Business Overview
Table 62. AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product
Table 63. AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 64. AET Biotech Recent Development
Table 65. Allergan Company Details
Table 66. Allergan Business Overview
Table 67. Allergan Monoclonal antibodies (mAbs) Biosimilars Product
Table 68. Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 69. Allergan Recent Development
Table 70. Amega Biotech Company Details
Table 71. Amega Biotech Business Overview
Table 72. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product
Table 73. Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 74. Amega Biotech Recent Development
Table 75. Research Programs/Design for This Report
Table 76. Key Data Information from Secondary Sources
Table 77. Key Data Information from Primary Sources
List of Figures
Figure 1. Monoclonal antibodies (mAbs) Biosimilars Product Picture
Figure 2. Global Monoclonal antibodies (mAbs) Biosimilars Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Monoclonal antibodies (mAbs) Biosimilars Market Size 2017-2028 (US$ Million)
Figure 4. United States Monoclonal antibodies (mAbs) Biosimilars Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 5. United States Monoclonal antibodies (mAbs) Biosimilars Market Size 2017-2028 (US$ Million)
Figure 6. United States Monoclonal antibodies (mAbs) Biosimilars Market Share in Global 2017-2028
Figure 7. Monoclonal antibodies (mAbs) Biosimilars Report Years Considered
Figure 8. Product Picture of Erythropoietin (EPO)
Figure 9. Product Picture of Human Growth Hormone (HGH)
Figure 10. Product Picture of Granulocyte- Colony Stimulating Factor (G-CSF)
Figure 11. Product Picture of Monoclonal Antibody (mAb)
Figure 12. Product Picture of Insulin
Figure 13. Product Picture of Interferon (IFN)
Figure 14. Product Picture of Others
Figure 15. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Type in 2022 & 2028
Figure 16. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2017-2028) & (US$ Million)
Figure 17. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2017-2028)
Figure 18. United States Monoclonal antibodies (mAbs) Biosimilars Market Share by Type in 2022 & 2028
Figure 19. United States Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2017-2028) & (US$ Million)
Figure 20. United States Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2017-2028)
Figure 21. Product Picture of Anti-Cancer
Figure 22. Product Picture of Anti-Inflammatory/Autoimmune
Figure 23. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application in 2022 & 2028
Figure 24. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2017-2028) & (US$ Million)
Figure 25. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2017-2028)
Figure 26. United States Monoclonal antibodies (mAbs) Biosimilars Market Share by Application in 2022 & 2028
Figure 27. United States Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2017-2028) & (US$ Million)
Figure 28. United States Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2017-2028)
Figure 29. North America Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate 2017-2028 (US$ Million)
Figure 30. U.S. Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 31. Canada Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 32. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate 2017-2028 (US$ Million)
Figure 33. Germany Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 34. France Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 35. U.K. Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 36. Italy Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 37. Russia Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 38. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate 2017-2028 (US$ Million)
Figure 39. China Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 40. Japan Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 41. South Korea Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 42. India Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 43. Australia Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 44. Taiwan Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 45. Indonesia Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 46. Thailand Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 47. Malaysia Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 48. Philippines Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 49. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate 2017-2028 (US$ Million)
Figure 50. Mexico Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 51. Brazil Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 52. Argentina Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 53. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate 2017-2028 (US$ Million)
Figure 54. Turkey Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 55. Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 56. U.A.E Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 57. Biocon Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 58. Celltrion Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 59. Dr. Reddy's Laboratories Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 60. Hospira Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 61. 3SBio Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 62. Accord Healthcare Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 63. AET Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 64. Allergan Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 65. Amega Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount